

14th November 2024

Ref : KIMIABL/COMP/BSE/24-25/

To
Department of Corporate Affairs- Listing
BSE Limited
Phiroz JeeJeebhoy Towers,
Dalal Street, Fort Mumbai-400001

Scrip Code: 530313 [KIMIABL]

Sub: Outcome of Board Meeting under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements), Regulations 2015.

Dear Sir/Madam,

The meeting of Board of Directors of the Company was held today on Thursday, November 14, 2024 at 7:00 P.M. (IST) at the corporate office of the Company, situated at 974, 9th Floor, Aggarwal Millennium Tower-II, Netaji Subash Place, New Delhi-110034 and the following businesses, amongst others, were transacted at the meeting of the Board of Directors.


1. Approval of un-audited financial results of the Company, on standalone basis, as at/for the quarter and three months ended September 30th 2024, in accordance with Regulation 33 of SEBI (Listing Obligation and Disclosure) Requirements) Regulations, 2015 and taking on record the Limited Review Report issued by the Statutory Auditor of the Company (copy attached as **Annexure A**).
2. Appointment of Mrs. Pallavi Garg (ACS- 69848) as the Company Secretary & Compliance Officer of the Company.

You are requested to take the above information on record and disseminate the same on your website.

The meeting was concluded at 07:30 P.M.

Thanking You,
Yours faithfully,

For **KIMIA BIOSCIENCES LIMITED**



Director

Sameer Goel
(Managing Director & CEO)

KIMIA BIOSCIENCES LIMITED
Regd. Office/Works
Village Bhondsi, Damdama Lake Road,
Gurugram, Haryana -122102
Tel.: +91 9654746544, 9654206544

Corporate Office
974, 9th Floor, Aggarwal Millenium Tower-II
Netaji Subhash Place, Pitampura, New Delhi-110034, INDIA
Tel: +91 11 47063600, 470630601

compliance.kimia@gmail.com | info@kimiabiosciences.com | www.kimiabiosciences.com | CIN No.: L24239HR1993PLC032120

Ref : KIMIABL/COMP/BSE/24-25/

To
Department of Corporate Affairs- Listing
BSE Limited
Phiroz JeeJeebhoy Towers,
Dalal Street, Fort Mumbai-400001

Dear Sir/Madam,

Scrip Code: 530313 [KIMIABL]

Sub: Intimation of appointment of Company Secretary - Disclosure under Regulation 30 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015

Pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligation and Disclosure Requirements) Regulations, 2015, we would like to inform you that:

1. Appointment of Mrs. Pallavi Garg (ACS- 69848) as the Company Secretary & Compliance Officer of the Company.

The additional details required under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended from time to time read with SEBI Circular No. CIR/CFD/CMD/4/2015 dated September 9, 2015 are enclosed as Annexure - 1.

Please take the above information on record and arrange for its dissemination.

Yours faithfully,

For **KIMIA BIOSCIENCES LIMITED**
For **KIMIA BIOSCIENCES LTD.**


Sameer Goel
(Managing Director & CEO) Director

Encl:

KIMIA BIOSCIENCES LIMITED
Regd. Office/Works
Village Bhondsi, Damdama Lake Road,
Gurugram, Haryana -122102
Tel.: +91 9654746544, 9654206544

Corporate Office
974, 9th Floor, Aggarwal Millenium Tower-II
Netaji Subhash Place, Pitampura, New Delhi-110034, INDIA
Tel: +91 11 47063600, 470630601

compliance.kimia@gmail.com | info@kimiabiosciences.com | www.kimiabiosciences.com | CIN No.: L24239HR1993PLC032120

Annexure - 1

Annexure-A

The details required under Regulation 30 of SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015 read with SEBI Circular No. CIR/CFD/CMD/4/2015 dated 09th September, 2015 is envisaged hereunder:


- 1) Appointment of Mrs. Pallavi Garg (ACS- 69848) as Company Secretary & Compliance Officer of Kimia Biosciences Limited.

Sr. No	Details of Events	Information of such events
1.	Date of Appointment	w.e.f 09.11.2024 vide approval in the Board Meeting dated 14.11.2024
2.	Brief Profile	As per Annexure-1
3.	Disclosure of relationship between directors	Mrs. Pallavi Garg (ACS- 69848) is not related to any of the Directors of the Company.

Annexure-1

Name of Company Secretary & Compliance Officer	Mrs. Pallavi Garg
Membership No:	ACS- 69848
Education Qualification	ACS
Brief Profile	Mrs. Pallavi Garg is having an experience in Secretarial Department She has a vast experience in handling: i) Convening of Board Meetings and Shareholder Meetings of Listed Company ii) E- voting and voting through postal ballots (iii) SEBI Regulations (iv) Stock Exchanges Compliances (v) Drafting and finalization of Agreements and MOU's (vi) Inter-se transfer of shares & Buy Back of shares

For KIMIA BIOSCIENCES LTD.



Director

KIMIA BIOSCIENCES LIMITED

Regd. Office/Works

Village Bhondsi, Damdama Lake Road,
Gurugram, Haryana -122102
Tel.: +91 9654746544, 9654206544

Corporate Office

974, 9th Floor, Aggarwal Millenium Tower-II
Netaji Subhash Place, Pitampura, New Delhi-110034, INDIA
Tel: +91 11 47063600, 470630601

compliance.kimia@gmail.com | info@kimiabiosciences.com | www.kimiabiosciences.com | CIN No.: L24239HR1993PLC032120

KIMIA BIOSCIENCES LIMITED

Regd. Office : Village Bhondsi, Tehsil Sohna, Dist. Gurgaon , Haryana - 122102

Phone: +91 9654746544, 9654206544 Email: compliance.kimia@gmail.com & info@kimiabiosciences.com

Website: www.kimiabiosciences.com, CIN : L24239HR1993PLC032120

UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND HALF YEAR ENDED SEPTEMBER 30, 2024


(₹ Lakhs except EPS)

S. No.	Particulars	Quarter ended			Half Year Ended		Year Ended
		30/09/2024	30/06/2024	30/09/2023	30/09/2024	30/09/2024	31/03/2024
		(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
I	Revenue from Operations	2,817.86	2,239.93	2,420.01	5,057.79	4,843.02	10,487.65
II	Other Income	37.09	8.33	63.74	45.42	76.26	164.18
III	Total Income (I+II)	2,854.95	2,248.26	2,483.75	5,103.21	4,919.28	10,651.83
IV	Expenses:						
	a) Cost of materials consumed	1,746.35	1,497.22	970.43	3,243.57	2,861.35	6,735.80
	b) Change in inventories of finished goods and work-in-progress	(20.95)	(274.57)	872.75	(295.52)	771.08	789.73
	c) Employee benefits expenses	352.45	342.83	389.52	695.28	788.22	1,515.25
	d) Finance costs	103.93	110.84	111.92	214.77	239.50	504.98
	e) Depreciation and amortisation expense	78.64	89.78	82.31	168.42	165.52	329.23
	f) Other expenses	403.10	303.96	383.47	707.06	782.42	1,495.21
V	Total Expenses (IV)	2,663.52	2,070.06	2,810.40	4,733.58	5,608.09	11,370.20
VI	Profit/(loss) before exceptional items and Tax (III-V)	191.43	178.20	(326.65)	369.63	(688.81)	(718.37)
VII	Exceptional Items	-	-	-	-	-	-
VI	Profit/(loss) before tax (IV-V)	191.43	178.20	(326.65)	369.63	(688.81)	(718.37)
VII	Tax expenses:						
	a) Current Tax	31.95	29.74	-	61.69	-	-
	b) Deferred Tax charge / (credit)	(1.86)	4.75	(82.48)	2.90	(173.59)	(187.50)
VIII	Profit/(loss) for the period (VI-VII)	161.34	143.70	(244.17)	305.04	(515.22)	(530.87)
IX	Other Comprehensive Income						
A.	Items that will not be reclassified to Profit or Loss (Net of Tax)						
	- Remeasurement of defined benefit plans	-	-	-	-	-	17.69
B.	Items that will be reclassified to Profit or Loss (Net of Tax)						
X	Total Comprehensive Income for the period (VIII+IX)	161.34	143.70	(244.17)	305.04	(515.22)	(513.18)
XI	Paid up equity share capital (Face value of Rs.1 per equity share)	473.13	473.13	473.13	473.13	473.13	473.13
XII	Other Equity						(440.03)
XIII	Earnings per equity share (not annualised)						
	Basic in Rs.	0.34	0.30	(0.52)	0.64	(1.09)	(1.12)
	Diluted in Rs.	0.34	0.30	(0.52)	0.64	(1.09)	(1.12)

STATEMENT OF ASSETS, EQUITY and LIABILITIES




S. No.	Particulars	As at 30-09-2024 (Unaudited)	As at 31-03-2024 (Audited)
A	ASSETS		
1	Non-Current Assets		
	Property, Plant & Equipment	3,047.04	3,149.96
	Capital Work-in-Progress	-	57.62
	Right of Use Assets	54.23	30.46
	Other Intangible Assets	2.58	4.09
	Deferred Tax Assets (Net)	575.53	578.43
	Financial Assets		
	(i) Other Non Current Financial Assets	36.30	26.32
	Other Non-current Assets	-	9.03
2	Current Assets		
	Inventories	3,367.92	3,080.35
	Financial Assets		
	(i) Investment	-	-
	(ii) Trade Receivables	2,496.38	2,755.40
	(iii) Cash and Cash Equivalents	33.22	14.76
	(iv) Bank balances other than (iii) above	44.37	38.68
	(v) Other Current Financial Assets	140.51	103.12
	Current Tax Assets (Net)	70.40	73.11
	Other Current Assets	23.67	75.33
	Total Assets	9,892.15	9,996.66
B	EQUITY & LIABILITIES		
1	EQUITY		
	(a) Share Capital	473.13	473.13
	(b) Other Equity	(134.99)	(440.03)
2	NON CURRENT LIABILITIES		
	Financial Liabilities		
	(i) Borrowings	1,807.43	2,140.98
	(ii) Lease Liabilities	40.99	18.45
	(iii) Other financial liabilities	606.84	580.71
	Provisions	160.45	144.90
	Other Non-Current Liabilities	109.75	134.75
3	CURRENT LIABILITIES		
	Financial Liabilities		
	(i) Borrowings	2,006.37	2,199.15
	(ii) Lease Liabilities	15.26	12.13
	(iii) Trade Payables		
	a. Total Outstanding due to Micro and Small Enterprises	4.73	4.95
	b. Total Outstanding due to other than Micro and Small Enterprises	3,824.63	3,993.87
	(iii) Other Financial Liabilities	519.25	506.63
	Other Current Liabilities	396.61	224.39
	Provisions	61.69	2.65
	Total Equity and Liabilities	9,892.15	9,996.66

KIMIA BIOSCIENCES LIMITED

Regd. Office : Village Bhonds, Tehsil Sohna, Dist. Gurgaon, Haryana - 122102

Phone: +91 9654746544, 9654206544 Email: compliance.kimia@gmail.com & info@kimiabiosciences.com

Website: www.kimiabiosciences.com, CIN : L24239HR1993PLC032120

UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND HALF YEAR ENDED SEPTEMBER 30, 2024



STATEMENT OF CASH FLOWS

Particulars	For the half year ended 30-09-2024 (Unaudited)	For the half year ended 30-09-2023 (Unaudited)
A. Cash Flow from Operating Activities		
Net Profit / (Loss) before tax	369.63	(688.81)
Adjustment for :		
Depreciation and amortization expense	168.42	165.52
Finance costs	214.77	239.50
Gain on fair value of investment in mutual funds	-	(0.02)
Interest income	-	(1.08)
Deferred revenue income	(0.68)	(25.00)
Unrealised (gain)/loss on foreign currency transactions and translations	-	(9.61)
Operating Profit Before Working Capital Changes	752.14	(319.50)
Adjustments for:		

Amun Jain




(Increase) / Decrease in inventories	(287.57)	1,163.58
(Increase) / Decrease in trade and other receivables	275.05	875.90
Increase / (Decrease) in trade and other payables	139.56	(1,394.71)
Cash Generated From Operations	879.18	325.27
Less : Income tax paid / (refunds)	2.71	(1.76)
Net Cash From Operating Activities	881.89	323.51
B. Cash Flow from Investment Activities		
Purchases of property, plant and equipments including intangible assets & capital advances	(95.03)	(56.60)
Net inflow / (outflow) in fixed deposits	(5.69)	(5.00)
Purchase of current investments	-	-
Interest received	0.68	-
Net Cash Used In Investing Activities	(100.04)	(61.60)
C. Cash Flow from Financing Activities		
Receipts from non current borrowings	-	-
Repayment of non current borrowings	(333.55)	(50.69)
Net proceeds of current borrowings	(192.78)	(61.57)
Finance costs paid	(237.72)	(152.66)
Net Cash Used In Financing Activities	(764.05)	(264.92)
Net Increase / (Decrease) in Cash and Cash Equivalents	17.81	(3.00)
Cash and Cash Equivalents at the beginning of the period	18.46	17.77
Cash and Cash Equivalents at the end of the period	33.22	21.11

Other Notes

1 The business activity of the Company falls within a single primary business segment viz 'Pharmaceuticals' and hence there is no other reportable segment as per Ind AS 108 'operating segments'.

Date: November 14, 2024
Place: New Delhi

FOR KIMIA BIOSCIENCES LIMITED



Sameer Goel
(Managing Director & CEO)
DIN - 00161786